Endologix Reports Positive Three-Year Results

Endologix, which is developing treatments for aortic disorders, presented positive three-year results from the Ovation European post-market registry data at a conference in Leipzig, Germany.

Through three years of follow-up, key study results included 99% freedom from aneurysm-related mortality,
99% freedom from migration, rupture, and conversion, the company said on Wednesday.

“The addition of these European results continue to validate the excellent clinical results and durability of the ultra-low profile Ovation platform, further confirming the recently announced 5-year Ovation IDE study results with real-world commercial data,” John McDermott, chief executive officer of Endologix, said.

Leave a Comment